The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features

Wilson, 1999, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum, 42, 1309, 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Mendes de Abreu, 2014, The use of GRADE system on autoimmune diseases: challenges for shared decision-making, Lupus, 23, 1292 Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011 de Jesus, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome, Autoimmun Rev, 13, 795, 10.1016/j.autrev.2014.02.003 Erkan, 2014, 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends, Autoimmun Rev, 13, 685, 10.1016/j.autrev.2014.01.053 Cervera, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome, Autoimmun Rev, 13, 699, 10.1016/j.autrev.2014.03.002 Arnaud, 2014, Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmun Rev, 22, 00240 Cervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum, 46, 1019, 10.1002/art.10187 0 Zuily, 2013, Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study, Thromb Res, 132, e1, 10.1016/j.thromres.2013.04.012 Leizorovicz, 2013, Clinical relevance of symptomatic superficial-vein thrombosis extension: lessons from the CALISTO study, Blood, 122, 1724, 10.1182/blood-2013-04-498014 Reynaud, 2014, Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis, Autoimmun Rev, 13, 595, 10.1016/j.autrev.2013.11.004 Yang, 2011, Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia, Korean J Intern Med, 26, 449, 10.3904/kjim.2011.26.4.449 Kim, 2013, Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies, Br J Haematol, 161, 706, 10.1111/bjh.12318 Dasanu, 2011, Isolated thrombocytopenia: should we routinely screen for antiphospholipid antibodies?, Conn Med, 75, 281 Diz-Kucukkaya, 2001, Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study, Blood, 98, 1760, 10.1182/blood.V98.6.1760 Stasi, 1994, Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura, Blood, 84, 4203, 10.1182/blood.V84.12.4203.bloodjournal84124203 Cervera, 2009, The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe, Lupus, 18, 889, 10.1177/0961203309106832 Italian Registry of Antiphospholipid Antibodies (IR-APA), 1993, Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry, Haematologica, 78, 313 Cuadrado, 1997, Thrombocytopenia in the antiphospholipid syndrome, Ann Rheum Dis, 56, 194, 10.1136/ard.56.3.194 1 Stojanovich, 2013, Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study, Clin Exp Rheumatol, 31 Comellas-Kirkerup, 2010, Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study, Blood, 116, 10.1182/blood-2010-05-283507 Krause, 2005, The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome, Immunobiology, 210, 749, 10.1016/j.imbio.2005.10.005 Erkan, 2012, APS ACTION — AntiPhospholipid Syndrome Alliance For Clinical Trials and International Networking, Lupus, 21, 695, 10.1177/0961203312437810 Levy, 2012, APS ACTION in Brazil, Braz J Rheumatol, 52, 813 Cervera, 2011, Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions, Lupus, 20, 165, 10.1177/0961203310395051 Nangaku, 1998, CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats, J Am Soc Nephrol, 9, 590, 10.1681/ASN.V94590 Seshan, 2009, Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies, Blood, 114, 1675, 10.1182/blood-2009-01-199117 Wu, 2013, Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions, Kidney Int, 83, 715, 10.1038/ki.2012.409 Amigo, 1992, Renal involvement in primary antiphospholipid syndrome, J Rheumatol, 19, 1181 Nochy, 1999, The intrarenal vascular lesions associated with primary antiphospholipid syndrome, J Am Soc Nephrol, 10, 507, 10.1681/ASN.V103507 Daugas, 2002, Antiphospholipid syndrome nephropathy in systemic lupus erythematosus, J Am Soc Nephrol, 13, 42, 10.1681/ASN.V13142 Tektonidou, 2004, Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome, Arthritis Rheum, 50, 7, 10.1002/art.20433 Glueck, 1985, Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants, Arch Intern Med, 145, 1389, 10.1001/archinte.1985.00360080059007 Kant, 1981, Glomerular thrombosis in systemic lupus erythematosus. Prevalence and significance, Medicine, 60, 71, 10.1097/00005792-198103000-00001 Tektonidou, 2008, Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary and systemic lupus erythematosus-related APS, J Rheumatol, 35, 1983 Song, 2013, The spectrum of thrombotic microangiopathy in lupus nephritis, Arthritis Res Ther, 15, R1, 10.1186/ar4142 Denas, 2014, Antiphospholipid syndrome and the heart: a case series and literature review, Autoimmun Rev, 14, 4 Petri, 2004, Classification criteria for antiphospholipid syndrome: the case for cardiac valvular, J Rheumatol, 31, 2329 Hollan, 2013, Cardiovascular disease in autoimmune rheumatic diseases, Autoimmun Rev, 12, 1004, 10.1016/j.autrev.2013.03.013 Espinola-Zavaleta, 2001, Two and three-dimensional echocardiography in primary antiphospholipid syndrome: misdiagnosis as rheumatic valve disease, Lupus, 10, 511, 10.1191/096120301678416097 Bouillanne, 1996, Prevalence and clinical significance of antiphospholipid antibodies in heart valve disease: a case–control study, Am Heart J, 132, 790, 10.1016/S0002-8703(96)90313-0 Kampolis, 2014, Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study, Semin Arthritis Rheum, 43, 558, 10.1016/j.semarthrit.2013.07.016 Stojanovich, 2012, Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study, Lupus, 21, 4, 10.1177/0961203311422710 Krause, 2005, Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome, Ann Rheum Dis, 64, 1490, 10.1136/ard.2004.032813 Espinola-Zavaleta, 2004, Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow-up study, J Rheumatol, 31, 2402 Amoroso, 2006, The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement, Clin Exp Rheumatol, 24, 287 Roldan, 2008, Transthoracic versus transesophageal echocardiography for detection of Libman–Sacks endocarditis: a randomized controlled study, J Rheumatol, 35, 224 Mattos, 2011, Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review, Clin Rheumatol, 30, 165, 10.1007/s10067-010-1662-5 Zuily, 2011, Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with SLE. Meta-analysis of echocardiographic studies, Circulation, 124, 215, 10.1161/CIRCULATIONAHA.111.028522 Diógenes, 2004, Cutaneous manifestations associated with antiphospholipid antibodies, Int J Dermatol, 43, 632, 10.1111/j.1365-4632.2004.01939.x Francès, 2005, Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases, Arthritis Rheum, 52, 1785, 10.1002/art.21041 Toubi, 2005, Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome, Clin Exp Rheumatol, 23, 499 Krause, 2007, Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis, Lupus, 16, 176, 10.1177/0961203306075977 Gómez-Puerta, 2005, Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?, Medicine (Baltimore), 84, 225, 10.1097/01.md.0000172074.53583.ea García-Carrasco, 2007, Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients, Lupus, 16, 366, 10.1177/0961203307077108 Mejía-Romero, 2008, Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients, Clin Rheumatol, 27, 891, 10.1007/s10067-007-0818-4 Williams, 2008, Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins, Cephalalgia, 28, 1048, 10.1111/j.1468-2982.2008.01646.x Cavestro, 2013, Migraineurs show a high prevalence of antiphospholipid antibodies, J Thromb Haemost, 9, 1350, 10.1111/j.1538-7836.2011.04348.x Asherson, 1987, Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies, Semin Arthritis Rheum, 16, 253, 10.1016/0049-0172(87)90003-5 Usugi, 2007, Familial antiphospholipid antibody in a child with involuntary movement and deterioration, Pediatr Int, 49, 238, 10.1111/j.1442-200X.2007.02346.x Orzechowski, 2008, Antiphospholipid antibody-associated chorea, J Rheumatol, 35, 2165, 10.3899/jrheum.080268 Reiner, 2011, Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies, Mov Disord, 26, 2422, 10.1002/mds.23863 Verrot, 1997, Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy, Am J Med, 103, 33, 10.1016/S0002-9343(97)90046-2 Cimaz, 2002, Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy, Epilepsia, 43, 52, 10.1046/j.1528-1157.2002.00701.x Peltola, 2000, Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders, Am J Med, 109, 712, 10.1016/S0002-9343(00)00617-3 Liimatainen, 2010, Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy, Epilepsia, 51, 760, 10.1111/j.1528-1167.2009.02325.x Herranz, 1994, Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus, Arthritis Rheum, 37, 57, 10.1002/art.1780370418 Mackworth-Young, 1985, Epilepsy: an early symptom of systemic lupus erythematosus, J Neurol Neurosurg Psychiatry, 48, 185, 10.1136/jnnp.48.2.185 Toubi, 1995, Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus, Am J Med, 99, 397, 10.1016/S0002-9343(99)80188-0 Liou, 1996, Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients, Lupus, 5, 307, 10.1177/096120339600500412 Kavassa, 2000, Risk factors for central nervous system involvement in systemic lupus erythematosus, QJM, 93, 169, 10.1093/qjmed/93.3.169 Mok, 2001, Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus, J Rheumatol, 28, 766 Sanna, 2003, Central nervous system lupus: a clinical approach to therapy, Lupus, 12, 935, 10.1191/0961203303lu505oa Appenzeller, 2004, Epileptic seizures in systemic lupus erythematosus, Neurology, 63, 1808, 10.1212/01.WNL.0000144178.32208.4F Mikdashi, 2004, Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort, Rheumatology, 43, 1555, 10.1093/rheumatology/keh384 Sachse, 1995, Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus, clinical and laboratory associations, Rheumatol Int, 15, 23, 10.1007/BF00286765 Formiga, 1997, Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients, Lupus, 6, 486, 10.1177/096120339700600515 D'Cruz, 2004, Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies, J Rheumatol, 31, 280 Birnbaum, 2009, Distinct subtypes of myelitis in systemic lupus erythematosus, Arthritis Rheum, 60, 3378, 10.1002/art.24937 Pengo, 2013, Correct laboratory approach to APS diagnosis and monitoring, Autoimmun Rev, 12, 832, 10.1016/j.autrev.2012.11.008 Roggenbuck, 2012, Antiphospholipid antibody profiling: time for a new technical approach?, Autoimmun Rev, 11, 821, 10.1016/j.autrev.2012.02.016 Hughes, 2003, Seronegative antiphospholipid syndrome, Ann Rheum Dis, 62, 1127, 10.1136/ard.2003.006163 Jawad, 2004, Classification vs diagnostic criteria — a revised international consensus statement on classification criteria for APS is required to accommodate the seronegative clinical entity, Ann Rheum Dis, 5, 608 Mahler, 2012, Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome, Autoimmun Rev, 12, 313, 10.1016/j.autrev.2012.05.006 Meijide, 2013, The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review, Autoimmun Rev, 12, 421, 10.1016/j.autrev.2012.08.002 Bertolaccini, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends, Autoimmun Rev, 13, 917, 10.1016/j.autrev.2014.05.001 Cervera, 2012, Does seronegative antiphospholipid syndrome really exist?, Autoimmun Rev, 11, 581, 10.1016/j.autrev.2011.10.017 Rodriguez-Garcia, 2012, Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’), Ann Rheum Dis, 71, 242, 10.1136/annrheumdis-2011-200614 Petri, 2010, Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort, Lupus, 19, 419, 10.1177/0961203309360541 Salcido-Ochoa, 2002, Antiprothrombin Antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome, J Clin Rheumatol, 8, 251, 10.1097/00124743-200210000-00004 Conti, 2012, Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome, Clin Exp Immunol, 167, 429, 10.1111/j.1365-2249.2011.04532.x